coronaviru
diseas
pandem
rage
throughout
globe
unit
state
alon
april
case
along
death
center
diseas
control
prevent
cdc
mathemat
model
creat
institut
health
metric
evalu
ihm
predict
unit
state
assum
continu
full
social
distanc
number
new
case
peak
late
april
relat
death
peak
midtol
may
creat
critic
immedi
need
medic
treatment
resourc
preliminari
data
us
suggest
may
infecti
lethal
influenza
gener
popul
current
casefat
rate
infect
rate
normal
condit
place
context
figur
provid
comparison
reproduct
rate
casefat
rate
major
respiratori
viru
pandem
data
strongli
emphas
earli
intervent
reduc
casefat
inhibit
reproduct
rate
number
articl
publish
clinic
cours
treatment
diseas
major
patient
present
one
symptom
admiss
although
combin
fever
cough
short
breath
rare
siddiqi
mehra
propos
stage
progress
model
base
observ
clinic
cours
publish
studi
stage
mild
phase
viru
multipli
establish
resid
host
predominantli
respiratori
tract
stage
see
viral
multipl
local
inflamm
lung
common
stage
mark
extrapulmonari
system
hyperinflamm
syndrom
prognosi
recoveri
stage
gener
poor
rapid
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
recognit
stage
patient
deploy
appropri
therapi
may
greatest
yield
common
correl
poorer
outcom
includ
age
hypertens
diabet
coronari
arteri
diseas
chronic
lung
diseas
malign
research
also
find
variat
outcom
due
dysregul
exuber
immun
respons
patient
requir
intens
care
significantli
higher
level
crp
ferritin
ddimer
import
therapeut
modal
may
downregul
cytokin
storm
particularli
sever
ill
literatur
also
suggest
diseas
progress
predict
sever
acut
respiratori
syndrom
sar
pandem
retrospect
analysi
reveal
week
cumul
case
data
could
help
estim
total
case
number
accuraci
well
date
last
report
case
found
unifi
framework
link
diseas
progress
establish
viral
level
clinic
test
inflammatori
marker
investig
treatment
option
given
may
take
mani
week
month
establish
standard
treatment
approach
grow
morbid
mortal
present
initi
treatment
approach
base
thorough
review
current
avail
scholarli
articl
clinic
report
focu
stage
progress
clinic
algorithm
individu
treatment
follow
protocol
qualiti
review
articl
propos
heyn
et
al
literatur
search
conduct
find
relev
studi
relat
search
conduct
april
april
use
follow
electron
databas
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
certifi
peer
review
copyright
holder
preprint
version
post
april
clinician
patient
understand
stage
progress
figur
present
treatment
algorithm
recommend
treatment
specif
treatment
other
depend
age
comorbid
symptom
sever
figur
base
thorough
review
literatur
correl
diseas
cours
test
diagnost
option
treatment
strategi
see
figur
divid
three
distinct
stage
begin
time
infect
stage
sometim
progress
pulmonari
involv
stage
ii
without
hypoxemia
less
frequent
system
inflamm
stage
iii
also
creat
treatment
algorithm
consid
age
comorbid
clinic
present
diseas
progress
suggest
drug
class
treatment
modal
see
figur
specif
treatment
summar
tabl
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
certifi
peer
review
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
data
exist
earli
identif
case
high
risk
progress
sever
one
promis
model
creat
china
found
patient
develop
sever
possess
one
follow
diseas
hypertens
diabet
coronari
heart
diseas
chronic
respiratori
diseas
tuberculosi
model
cite
age
variou
serolog
indic
creactiv
protein
crp
lactat
dehydrogenas
ldh
bilirubin
other
factor
associ
wors
outcom
addit
research
confirm
casecontrol
studi
subject
high
sequenti
organ
failur
assess
sofa
score
age
greater
hypertens
diabet
andor
coronari
heart
diseas
greatest
risk
lastli
research
focus
viral
load
surviv
found
higher
initi
viral
load
independ
associ
wors
prognosi
common
present
symptom
fever
cough
follow
myalgia
fatigu
less
commonli
patient
may
present
sputum
product
headach
abdomin
symptom
like
diarrhea
term
diseas
progress
case
studi
first
five
patient
diagnos
europ
point
way
two
differ
clinic
evolut
diseas
present
symptom
show
high
viral
load
respiratori
tract
twostep
diseas
process
worsen
symptom
around
day
symptom
onset
spite
decreas
viral
load
respiratori
sampl
model
plot
diseas
progress
function
infect
surviv
inflamm
figur
identifi
inflect
point
surviv
decreas
inflamm
increasesapproxim
day
symptom
onset
support
found
research
chen
j
qi
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
research
found
sepsi
ard
hospit
patient
start
around
day
respect
also
found
tempor
chang
inflammatori
laboratori
marker
begin
day
ill
onset
includ
tempor
chang
ddimer
serum
ferritin
highsensit
cardiac
troponin
lactat
dehydrogenas
differ
statist
signific
survivor
nonsurvivor
time
point
figur
provid
percent
chang
survivor
nonsurvivor
day
addit
yang
et
al
found
patient
admit
icu
sever
hypoxemia
probabl
surviv
day
icu
admiss
correspond
day
figur
incub
period
averag
day
patient
initi
present
symptom
mild
though
small
number
patient
asymptomat
throughout
cours
diseas
stage
symptom
includ
fever
cough
fatigu
bodi
ach
minor
case
includ
headach
gi
symptom
anosmia
well
other
durat
initi
symptom
day
correl
peak
viral
load
time
appropri
diagnost
test
nasopharyng
pcr
laboratori
studi
may
includ
elev
ddimer
prothrombin
time
well
lymphopenia
see
figur
given
symptom
stage
mild
correl
viremia
appropri
treatment
modal
support
care
antivir
nevertheless
treatment
must
individu
base
patient
age
comorbid
present
symptom
drug
interact
see
figur
tabl
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
patient
progress
stage
ii
character
decreas
viral
level
increas
inflamm
initi
local
lung
infiltr
typic
seen
chest
xray
cxr
comput
tomographi
ct
similar
symptom
durat
stage
typic
symptom
cours
stage
ii
also
day
treatment
antivir
still
indic
given
averag
decreas
viral
level
stage
treatment
theoret
less
effect
stage
moreov
stage
ii
divid
two
substag
iia
iib
depend
whether
patient
hypoxem
distinct
import
manag
see
figur
stage
iib
patient
significantli
dyspneic
may
benefit
depend
age
comorbid
use
corticosteroid
antiinflammatori
treatment
see
figur
although
minor
patient
estim
progress
stage
iii
mortal
within
stage
consider
estim
morbid
mortal
gener
due
uncontrol
inflamm
point
system
import
symptom
respiratori
distress
correl
typic
patient
puls
ox
laboratori
marker
includ
significantli
increas
crp
level
stage
ii
treatment
may
includ
antivir
patient
still
virem
agent
counteract
inflamm
effect
microthrombi
must
consid
see
figur
summari
investig
therapi
found
tabl
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
number
clinic
trial
explor
preexposur
postexposur
prophylaxi
definit
evid
particular
treatment
modal
effect
antivir
hydroxychloroquin
convalesc
plasma
propos
antivir
like
remdesivir
may
proof
benefici
stage
diseas
hydroxychloroquin
postul
antivir
properti
definit
proven
immunomodul
convalesc
plasma
provid
antibodi
support
need
envelop
destroy
viru
prevent
exuber
immun
respons
cytokin
releas
lead
signific
patholog
particularli
stage
iib
iii
review
sever
limit
first
incred
volum
speed
data
publish
treatment
indic
research
find
recommend
may
chang
second
research
use
creat
review
came
small
studi
oftentim
control
third
articl
limit
englishlanguag
public
translat
relev
intern
data
could
lack
paper
present
first
evidencebas
recommend
individu
treatment
base
upon
observ
transmiss
mortal
rate
health
profession
urgent
need
align
patient
baselin
risk
diseas
stage
investig
treatment
option
pandem
repres
greatest
public
health
crisi
three
gener
need
comprehens
manag
overst
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
certifi
peer
review
copyright
holder
preprint
version
post
april
authorfund
grant
medrxiv
licens
display
preprint
perpetu
certifi
peer
review
copyright
holder
preprint
version
post
april
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
certifi
peer
review
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
